Subcutaneous infliximab in inflammatory bowel disease: from pharmacokinetic principles to clinical practice.

Authors

Mohammed Nabil Quraishi, Sara El Ouali

Published in

Expert opinion on biological therapy. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

Subcutaneous infliximab (CT-P13 SC) was developed to address the pronounced peak-to-trough fluctuations of intravenous dosing and the immunogenicity driven by sub-therapeutic troughs. Through a stable steady-state pharmacokinetic profile it meets the international Delphi consensus definition of a biobetter, although this is not a regulatory designation.
This narrative review synthesizes pivotal Phase 3 trial data, randomized comparisons of continued intravenous versus subcutaneous maintenance, real-world switching cohorts, individual participant data meta-analyses, and emerging evidence on therapeutic drug monitoring recalibration, immunomodulator de-escalation, and special populations including obesity, perianal disease, pediatric inflammatory bowel disease, and pregnancy. MEDLINE, Embase, and the Cochrane Library were searched from inception to August 2026.
Subcutaneous infliximab is positioned to become the default maintenance route for most patients, with intravenous administration reserved for acute, high-burden induction. Within five years, fully subcutaneous pathways, immunomodulator de-escalation guided by steady-state levels, and dosing informed by individual clearance are expected to move from research questions to standard practice.

PMID:
42844215
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.